tetano
Editor, Senior Moderator
Lancet Child Adolesc Health
. 2023 Jan 24;S2352-4642(22)00315-7.
doi: 10.1016/S2352-4642(22)00315-7. Online ahead of print.
Lessons learnt from influenza vaccination in immunocompromised children undergoing treatment for cancer
Eliska Furlong[SUP] 1 [/SUP], Rishi S Kotecha[SUP] 2 [/SUP]
Affiliations
Abstract
Influenza infection contributes substantially to global morbidity and mortality, with children undergoing treatment for cancer among the most vulnerable due to immunosuppression associated with disease and treatment. However, influenza remains one of the most common vaccine-preventable diseases. Despite international guidelines recommending inactivated influenza vaccination on the basis of data supporting efficacy and an excellent safety profile in this population, uptake has often been suboptimal due to persisting hesitancy among both patients and oncologists regarding the ability of the vaccine to mount a sufficient immune response, the optimal vaccine schedule and timing, and the best method to assess response in immunocompromised populations. In this Review, we discuss the evidence regarding influenza vaccination in children with cancer, factors that influence response, and highlight strategies to optimise vaccination. Host immune factors play a substantial role, thus principles learnt from influenza vaccination can be broadly applied for the use of inactivated vaccines in children with cancer.
. 2023 Jan 24;S2352-4642(22)00315-7.
doi: 10.1016/S2352-4642(22)00315-7. Online ahead of print.
Lessons learnt from influenza vaccination in immunocompromised children undergoing treatment for cancer
Eliska Furlong[SUP] 1 [/SUP], Rishi S Kotecha[SUP] 2 [/SUP]
Affiliations
- PMID: 36706776
- DOI: 10.1016/S2352-4642(22)00315-7
Abstract
Influenza infection contributes substantially to global morbidity and mortality, with children undergoing treatment for cancer among the most vulnerable due to immunosuppression associated with disease and treatment. However, influenza remains one of the most common vaccine-preventable diseases. Despite international guidelines recommending inactivated influenza vaccination on the basis of data supporting efficacy and an excellent safety profile in this population, uptake has often been suboptimal due to persisting hesitancy among both patients and oncologists regarding the ability of the vaccine to mount a sufficient immune response, the optimal vaccine schedule and timing, and the best method to assess response in immunocompromised populations. In this Review, we discuss the evidence regarding influenza vaccination in children with cancer, factors that influence response, and highlight strategies to optimise vaccination. Host immune factors play a substantial role, thus principles learnt from influenza vaccination can be broadly applied for the use of inactivated vaccines in children with cancer.